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The disappointingly slow progress in developing effective
therapies for ischemic stroke has led to a re-evaluation of
the strategies for stroke drug development and the
methods used in clinical trials. Magnetic resonance
imaging (MRI) techniques have been proposed and have
begun to be used in stroke trials as a means of optimizing
patient selection and as a direct measure of the effect of
treatments on the brain.
One objective in all clinical trials is the selection of a
sample that is sufficiently homogeneous to reduce the sta-
tistical variance of the data and thereby optimize the sensi-
tivity of the design to detecting a therapeutic response,
while remaining representative of the population of inter-
est. Ischemic stroke trials have traditionally sought to limit
the range of disease studied according to one or more of
several dimensions, such as clinical severity at the time of
enrollment, exclusion of non-ischemic causes for the clini-
cal syndrome, lesion location and vascular territory, stroke
mechanism, and co-morbidities. These dimensions have
been assessed in the modern era of stroke clinical trials by
clinical criteria at the bedside, usually aided by the exclu-
sion of cerebral hemorrhage or other non-ischemic pathol-
ogy by non-contrast computed tomography (CT) scan as
the only imaging tool required. Except for the trials of intra-
venous recombinant tissue-plasminogen activator (rt-PA)
in the treatment of ischemic stroke within the first 3 h [1],
this traditional approach has lead to no approved thera-
pies for stroke, and has lead to a great degree of pes-
simism with regard to thrombolysis beyond 3 h and with
regard to the concept of neuroprotection in stroke.
Because several imaging modalities may provide more
accurate and specific information than a clinical assess-
ment and a normal CT scan, it has been proposed that
positive imaging diagnoses would improve patient selec-
tion toward the goal of a more optimal target sample for
stroke clinical trials, a sample selected based on an
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imaging diagnosis of a pathology that the drug is hypothe-
sized to treat; for example, an arterial occlusion or perfu-
sion defect for thrombolytic drugs. This principle has been
supported by the results of the intra-arterial pro-urokinase
stroke study, PROACT II [2]. Prior attempts to prove the
efficacy of thrombolysis initiated between 3 and 6 h from
onset without a positive diagnosis of arterial occlusion or
perfusion defect have not been successful [3–5]. Patients
in PROACT II [2], however, were selected based on evi-
dence of arterial occlusions at the M1 or M2 levels of the
middle cerebral artery by conventional arteriography, and a
significant clinical benefit was observed when thromboly-
sis was initiated up to 6 h from symptom onset (median
time to treat, 5.3 h). Whereas trials of intravenous (IV)
thrombolysis between 3 and 6 h in a general sample of
ischemic stroke patients were not positive, selection of the
optimal subgroup by imaging diagnosis of the appropriate
arterial lesion was an effective strategy in this time period
for PROACT II. This study contradicted the increasingly
promoted hypothesis that treatment of stroke by thrombol-
ysis (or any therapy) beyond 3 h would not be successful.
Selection of the optimal target population by angiography
led to slower recruitment and a more expensive trial, but to
a successful result. The results of that trial suggested that
a more prolonged study duration, increased expense and
potential delay in treatment to complete a screening test
may be justified by the greater chance of demonstrating
therapeutic success using a more homogeneous and
rational selection of patients.
The appeal of MRI methods is that, whereas the standard
CT examination of acute ischemic stroke will typically
appear normal in the first hours after stroke onset, the
methods of magnetic resonance angiography, perfusion
weighted imaging (PWI), and diffusion weighted imaging
(DWI) provide information on arterial patency, tissue blood
flow, and parenchymal injury from the earliest times after
onset of ischemic symptoms in a brief, non-invasive exami-
nation. DWI (Fig. 1) detects tissue injury within minutes of
ischemia, has high sensitivity and specificity for the diagno-
sis of ischemic stroke, and permits measurement of lesion
volumes that correlate with clinical severity and prognosis
[6–12]. If untreated, the lesion seen with DWI typically
enlarges over hours to days and will progress to infarction.
PWI depicts focal cerebral ischemia. The volume of
ischemic tissue seen with PWI, in the majority of cases, is
greater than the region of parenchymal injury evident on
DWI, and this diffusion–perfusion mismatch is considered
to be a marker of the ischemic penumbra (Fig. 2), the
tissue at greatest risk for infarct progression [13–21]. Fur-
thermore, increasing theoretical, experimental, and clinical
evidence suggests that MRI using magnetic susceptibility
weighted pulse sequences may be sensitive to the early
detection of hemorrhage [22–24]. Although prospective
comparisons of MRI and CT for sensitivity to hemorrhage
detection have yet to be reported, the proper acquisition
and interpretation of MRI can eliminate the need for a
screening CT scan and regain some of the time spent on
adding a MRI examination to a screening evaluation. The
target pathology revealed by MRI also represents the bio-
logical marker of the disease that can serve as a surrogate
measure for assessing the effects of a therapy.
Three potential uses of MRI in clinical trials have been pro-
posed: patient selection, proof of pharmacologic principle,
and as an outcome measure.
In using MRI as a selection criterion in patient selection
(Table 1), the goal would be a sample based on a positive
imaging diagnosis of a pathology rationally linked to the
drug’s mechanisms of action. Requiring a positive diagno-
sis of acute ischemic injury by DWI would ideally assure
that no patients with diagnoses mimicking stroke are
included in the sample, a desirable objective unachievable
in trials using bedside impression and normal CT as the
basis of inclusion. The goal of image-based patient selec-
tion is to narrow the range of patient characteristics,
leading to a more homogeneous sample, reducing within-
group variance, and increasing the statistical power of the
experimental design to demonstrate efficacy. Optimal
patient selection would be based on positive imaging evi-
dence of the ischemic pathology that the therapy has been
developed to treat. The simplest use as an inclusion crite-
rion would include the presence of a lesion on DWI to
increase the diagnostic certainty of ischemic stroke. The
optimal target of therapy for reperfusion therapies would be
patients with evidence of an arterial occlusion or hypoper-
fusion (Fig. 3) [17,25]. Optimal selection of patients for
neuroprotective drugs would be acute lesions involving the
cerebral cortex and with a larger region of hypoperfusion —
the diffusion–perfusion mismatch indicative of tissue at risk
for infarction (Fig. 2 and Table 2). Patients might also be
excluded from the trial at screening if subacute or chronic
lesions are found that may confound measurements of
lesion volumes or clinical severity as outcome variables.
Because of a relatively large error of measurement associ-
Table 1
Proposed uses of magnetic resonance imaging (DWI, PWI, and
MRA) as a selection tool in stroke trials
Positive radiological diagnosis of ischemic lesion by DWI
Select by location (eg cortical, MCA territory, etc)
Select by size (DWI)
Select by perfusion defect (PWI, MRA) for reperfusion therapies
Select by diffusion/perfusion mismatch (DWI, PWI) for neuroprotective
drugs
Exclude if confounding subacute or chronic lesions
DWI, diffusion weighted imaging; MCA, middle cerebral artery; MRA,
magnetic resonance angiography; PWI, perfusion weighted imaging.Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 1 Warach
ated with small lesions [26], lesions larger than a minimum
volume (eg 5 cm3) may be desirable. Furthermore, an
upper limit of lesion volume at enrollment would permit an
opportunity for lesion growth and may better differentiate
the effect on lesion size of an effective treatment from
placebo. Selection of patients by DWI is also optimally
suited for using the lesion volume change as a direct
measure of the neuroprotective effect of the drug.
The proof of pharmacological principle uses MRI as a
marker of response to therapy, replicating the preclinical
experiment in patients. Before an experimental stroke
therapy is brought from the laboratory to clinical trial, it is
necessary to demonstrate that the treatment causes
reduction in lesion volume in experimental models. The
fundamental premise of drug discovery and development
in acute stroke is that treatments that reduce lesion size
are those most likely to lead to clinical benefit. In clinical
trial programs that depend solely on clinical endpoints as
indices of benefit, drugs may be brought to phase III
testing — costing several years and tens of millions of
dollars — without the slightest evidence that the drug will
Figure 1
The diffusion weighted imaging (DWI) of 3 h stroke. (a) The fluid-
attenuated inversion recovery image without diffusion weighting shows
no acute lesion. (b) DWI demonstrates the acute lesion as a region of
hyperintensity (brightness) in the left temporal lobe.
Table 2
The diffusion–perfusion mismatch
MRI marker of the ischemic penumbra
The strongest predictor of lesion growth from baseline
Present in approximately 80% of MCA territory strokes up to 6 h
poststroke
Distinction of benign hypoperfusion from true tissue at risk not yet
possible prospectively
MRI, magnetic resonance imaging; MCA, middle cerebral artery.
Figure 3
Example of magnetic resonance imaging based selection for
thrombolysis. (a) Magnetic resonance angiography demonstrates right
middle cerebral artery occlusion (arrow). (b) Two representative
perfusion weighted imaging slices demonstrate delayed relative mean
transit time in the entire right middle cerebral artery (MCA) territory. 
(c) Two corresponding diffusion weighted imaging slices demonstrate
parenchymal injury only in the deeper parts of the right MCA territory
(arrows), a diffusion–perfusion mismatch. Following tissue-type
plasminogen activation (tPA) therapy, recanalization of the right MCA
is seen (d), with normalization of perfusion (e), and limitation of the
parenchymal damage (f).
Figure 2
The diffusion–perfusion mismatch. A small lesion on the diffusion
weighted image (DWI) in a 3 h stroke relative to the larger perfusion
weighted image abnormality on a relative mean transit time (MTT) image.have the therapeutic effect observed in the experimental
model. Only a safe and acceptable dose must be demon-
strated by the end of phase II. The question of whether the
treatment causes reduction of lesion volume, however,
may be answerable in the study of 100–200 patients in
phase II, whereas 5–10 times as many patients are typi-
cally tested in phase III studies to evaluate the treatment
with clinical endpoints. A phase II MRI endpoint trial to
replicate the preclinical experiment in a patient population
may thus be a rational and cost-effective basis of deciding
whether to proceed with phase III testing. A positive lesion
outcome study in late phase II would be supportive of the
decision to proceed with phase III trials.
MRI measurements have proven to be a marker of clinical
severity measured by stroke scales [11,15,27,28], and
changes in lesion volume over time are associated with
change in clinical severity (Table 3) [29]. The exact sample
size that is required for detecting the effect of lesion volume
change with MRI will depend on many factors in the design
of a trial. The citicoline MRI trial [29], with approximately 40
evaluable patients per group, approached but did not reach
significance. Estimates based on that study indicate that 58
patients per treatment arm would have been sufficient to
demonstrate a neuroprotective effect in patients, a sample
size compatible with typical phase II sample sizes. That
study and natural history samples suggest that a sample
size of 50–100 should be sufficient to demonstrate a neuro-
protective effect on lesion volume in patients.
It is proposed that a treatment emergent advantage on a
measure of lesion volume is a surrogate of clinical benefit
for stroke trials (Table 4). The rationale for the use of
lesion volume as a surrogate measure in stroke trials may
be summarized as follows. Lesion volume reduction in
animal models is both necessary and sufficient evidence
of neuroprotection. The clinical benefit for neuroprotective
drugs is mediated through a reduction in cell death and
brain tissue loss. Drugs that reduce infarct volume are
those most likely to cause clinical benefit.
The factors required for validation of MRI as a surrogate
marker are summarized in Table 5. The first four of these
requirements have been met (see earlier discussion and
cited references). Confirmation of the validity of many of
these features of DWI and PWI in acute stroke has
recently come from the first prospective multicenter stroke
trial using MRI as an inclusion and primary outcome
measure, the citicoline MRI stroke trial [29]. In that study,
identical MRI hardware and software were used in 17
centers across the United States to study 100 patients
with ischemic stroke within 24 h of onset. Patients were
randomly assigned to 500 mg/day citicoline or placebo.
Diffusion and perfusion MRI were obtained before treat-
ment, and 1 and 12 weeks after treatment. Image data
processing and volumetric analysis were performed at a
single central laboratory using a single expert reader
blinded to patient clinical severity and treatment assign-
ment. The primary MRI inclusion criterion was a lesion of
Available online http://cvm.controlled-trials.com/content/2/1/038
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Table 3
Magnetic resonance imaging as a biomarker of clinical status
[29]
Acute lesion volumes correlated with clinical scales and with final
lesion volumes
Strong association of reduction in lesion volume with clinical
improvement:*
% patients  Median  Mean 
Clinical with  lesion change  change 
improvement decrease† (cm3)‡ (SE) (cm3)†
Yes 74 –2.8 3.8 (3.8)
No 36 3.7 25.5 (6.8)
*Week 12 minus baseline lesion volume change related to clinical
improvement (n = 81, from [29]). SE, standard error. †P < 0.001; 
‡P < 0.01.
Table 4
Magnetic resonance imaging as outcome measure
Necessary but not sufficient evidence of protective effect
Protective effect may be attenuation of expected lesion growth or
partial DWI lesion reversal
Clinical benefit unlikely if no protective effect on lesion volume (go/no
go decision at phase II)
Smaller sample size requirements than for typical clinical endpoints
(~50–100 per arm)
May be confirmatory evidence supporting positive clinical endpoint trial
for regulatory approval
DWI, diffusion weighted imaging.
Table 5
Requirements of a validated surrogate for DWI and PWI
To fully establish diffusion and perfusion MRI as a useful tool and
validated surrogate in stroke trials, several conditions need to be
satisfied (the first four have been met; see text):
1.  DWI and PWI as biologic markers of the disease process in 
ischemic stroke
2.  The tests are sensitive and specific for the diagnosis of stroke 
in patients
3.  Lesion volumes correlate with clinical function as measured by 
clinical rating scales, predict outcome, and co-vary over time 
with clinical severity
4.  Rational co-variates affecting lesion volumes identified
5.  Utility in identifying effective treatments in trials proven
DWI, diffusion weighted imaging; MRI, magnetic resonance imaging;
PWI, perfusion weighted imaging.Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 1 Warach
volume 1–120 cm3 in middle cerebral artery territory gray
matter. The primary efficacy endpoint was a change in
lesion volume from pretreatment to week 12. Although the
primary efficacy endpoint of an effect of citicoline on
lesion growth was numerically different (181% increase in
lesion volume in placebo patients versus 34% increase for
citicoline treated patients), it was not statistically signifi-
cant. However, the study replicated the findings of other
investigations regarding the relationship of MRI-derived
lesion volumes to patients’ clinical status. Acute lesion
volumes by DWI in 100 patients correlated significantly
with acute clinical severity on NIH stroke scale scores
(r = 0.64) and with chronic lesion volume (r = 0.79); the
chronic lesion volume by T2-weighted MRI significantly
correlated with chronic NIH stroke scale score (r = 0.63).
The strongest predictor of change in lesion size from
baseline in the 81 patients who completed their week 12
assessment was the size of the perfusion abnormality
(P < 0.0001 by co-variance analysis). The volume change
over the 12 weeks of observation was significantly related
to the patient’s clinical improvement. Patients meeting the
protocol specified criterion of clinical improvement
(improvement on the NIH stroke scale of seven points or
more) had a significantly more favorable response on the
lesion volume change outcome variable than those who
did not improve. The differentiation of improved from not
improved was present whether the lesion volume change
was assessed as an absolute decrease (74% versus
36%), median change (–2.8 cm3 versus 3.7 cm3), or mean
(SE) change (3.8 [3.8] cm3 versus 25.5 [6.8] cm3)
(Table 5). This prospective multicenter, centrally analyzed
trial confirmed the value of MRI as a marker of disease
severity and progression in stroke trials, and indicated that
the change in MRI lesion size is likely to predict clinical
improvement in clinical trials.
The fifth criterion of validation, the concordance of effects
on clinical outcomes and surrogate outcomes, remains to
be demonstrated. Effective drugs will show benefit on both
clinical and imaging outcome measures. The citicoline trials
provide support for this, wherein trends on both clinical
and imaging outcomes measures have been observed
[29–32]. Ineffective drugs will show benefit on neither clini-
cal nor imaging outcome measures. The latter has been
found for the Glycine Antagonist in Neuroprotection
(GAIN) trials, which showed no effect on clinical or MRI
surrogate outcomes [33,34]. This comparison is only
meaningful if studies are optimally designed and equally
powered to show effect on their respective outcome mea-
sures; that is, the optimal sample size for imaging studies
may be too small to show clinical effects. Possible explana-
tions for discordant clinical versus surrogate marker results
are presented in Table 6.
The concept that improvement as a measure of brain lesion
volume is a proper surrogate outcome for destructive
central nervous system diseases has been already
accepted by academic and regulatory communities alike.
Approval of beta-interferon for the treatment of multiple
sclerosis was based, in part, on lesion volume as a surro-
gate marker of disease activity, even though the surrogate
was not considered fully validated. A surrogate outcome
measure in clinical trials does not need to be fully validated
as a condition of drug approval. Recent changes to the
Federal Food Drug and Cosmetic Act, which regulates the
Food and Drug Administration approval process, have
specified a fast-track drug designation to expedite review
for drugs that have “the potential to address unmet medical
needs for serious and life-threatening conditions” [35].
Drugs for treatment of stroke have fallen under this desig-
nation. A drug must ordinarily have a beneficial effect on a
clinical endpoint or on a validated surrogate endpoint to
demonstrate effectiveness. The new regulations state that
a drug “may be approved if it has an effect on a surrogate
endpoint that is reasonably likely to predict clinical benefit.
Such surrogate endpoints are considered not to be vali-
dated because, while suggestive of clinical benefit, their
relationship to clinical outcomes, such as morbidity and
mortality, is not proven” [35] (emphasis added). The issue
with regard to MRI as a surrogate in stroke trials is whether
it is ‘reasonably likely to predict clinical benefit’. The
hypothesis that neuroprotection, the restriction of infarct
volume, is reasonably likely to be clinically beneficial to
patients is the premise of virtually all acute stroke drugs
being developed. The clinical data already discussed sup-
ports the value of measuring infarct value as a surrogate.
Strict validation must eventually be proven but, as we see
from Food and Drug Administration regulations, it is no
longer required to use lesion volume by MRI as a surrogate
outcome in stroke trials. A benefit on the surrogate may be
acceptable as an independent source of confirmatory data
in support of a clinical benefit seen in a single trial. The
question, therefore, is no longer whether MRI surrogates
should be used in trials, but how they should be used.
The pharmaceutical industry has taken the initiative in
investigating this final step in validation. The results of
Table 6
Validation of magnetic resonance imaging lesion volumes as a
surrogate outcome: explanations of possible discordance
between clinical and surrogate lesion volume measures
If clinical endpoint shows a benefit but lesion volume does not:
Imaging methods are insensitive to neuroprotection
Clinical benefit not mediated by neuroprotection
If lesion volume shows a benefit but the clinical endpoint does not:
Trial design or clinical measures are insensitive to detecting a 
clinical effect
Toxicity offsets neuroprotective effectAvailable online http://cvm.controlled-trials.com/content/2/1/038
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several industry-sponsored drug trials using MRI as a sur-
rogate will be known over the next several years, and
those studies should provide the most decisive informa-
tion regarding the utility of MRI as a surrogate outcome
measure in stroke trials. Three multicenter randomized
clinical trials using MRI as a key selection and outcome
variable have been completed and reported. Several other
trials are in progress or being planned.
In conclusion, there have been concerns raised in the past
that the use of MRI in stroke clinical trails is impractical for
technical and logistical reasons (eg scan duration and
availability). The practical limitations have disappeared
with the widespread availability of ultrafast echoplanar
imaging with diffusion and perfusion capability on com-
mercial MRI scanners. A highly motivated, well-coordi-
nated center can perform emergency diffusion and
perfusion MRI with a latency to scan and scanning session
duration comparable with that of emergency head CT.
There are now over 100 centers worldwide capable of
and experienced in performing these types of acute MRI
examinations. Key design issues with regard to the use of
diffusion and perfusion MRI in stroke trials are proposed in
Table 7. MRI-based recruitment into trials with a time
window of 6 h has proven feasible, as has specific selec-
tion based on lesion size, location, and the diffusion–per-
fusion mismatch. As the field of stroke clinical trials
examines opportunities for improving trial design, positive
imaging diagnoses in patient selection and use of imaging
as treatment assessments is likely to assume an increas-
ingly useful role. Patient selection and outcomes based
exclusively on clinical assessment and non-hemorrhagic
CT scans may no longer be appropriate for all trials.
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